A Life Sciences PR agency is a communications firm that manages the public image and media presence of pharmaceutical companies, medical device manufacturers, CROs, CDMOs, and digital health providers. It handles media relations, thought leadership, clinical milestone announcements, and funding announcements. These agencies understand the regulatory boundaries and medical literacy that general PR firms lack, giving them the editorial relationships that matter in this space.
For life sciences companies, we target specialist outlets such as STAT News, Fierce Pharma, BioPharma Dive, Endpoints News, and MedCity News for trade and industry credibility. For scientific audiences, we work toward coverage in Nature Medicine, NEJM, and The Lancet. For broader public and policy reach, we target Reuters Health, Bloomberg Health, and WSJ Health around major clinical milestones and regulatory news.
We start by mapping your clinical pipeline, funding milestones, and publication calendar, then identify the narratives your investors, partners, and specialist journalists are already responding to. From there we build a 90-day plan and run media outreach, thought leadership, and embargo coordination at the same time rather than one after the other, so the program keeps building instead of starting over after each announcement. This is the foundation of our proprietary PR framework for tech companies, built to turn expertise into visibility and visibility into pipeline.
Most Life Sciences PR programs deliver first trade media coverage within 4 to 6 weeks. Deeper results take 6 months or more to develop, including consistent specialist media presence, KOL relationships, and credibility with investors and payers. Major milestones like Phase 3 readouts or regulatory approvals can generate concentrated coverage within days when managed well. Life sciences reputation is built slowly and lost quickly, so the program is designed for sustained presence rather than single spikes.
PRLab works with pharmaceutical companies, medical device manufacturers, CROs, CDMOs, and digital health providers across Europe, the U.S., MENA, and LATAM. We focus exclusively on B2B life sciences and healthcare technology, from early-stage biotechs building their first media presence to enterprise companies managing complex multi-market communications.
We work with life sciences companies from Seed stage onwards. Seed and Series A companies focus on first media coverage, early investor awareness, and establishing scientific credibility. Series B and growth stage companies shift toward category authority, executive positioning, and commercial launch support. Enterprise clients prioritise market position, share of voice, and regional visibility across multiple regulatory environments. The program scales with the business at every stage.
